Table 2.
PDL1 expression in patients with different EGFR status, ALK status, and histology.
| PCR expression | 22C3 | SP142 | SP263 | ||||
|---|---|---|---|---|---|---|---|
| TC ≥ 1% | IC ≥ 1% | TC ≥ 1% | IC ≥ 1% | TC ≥ 1% | IC ≥ 1% | ||
| EGFR-positive | 38/79 (48%) | 31/81 (38%) | 39/81 (48%) | 19/81 (23%) | 47/81 (58%) | 45/81 (56%) | 60/81 (74%) |
| EGFR-negative | 149/358 (42%) | 153/392 (39%) | 217/392 (55%) | 82/392 (21%) | 187/392 (48%) | 196/392 (50%) | 264/392 (67%) |
| ALK-positive | 17/37 (46%) | 17/37 (46%) | 12/37 (32%) | 13/37 (35%) | 14/37 (38%) | 17/37 (46%) | 12/37 (32%) |
| ALK-negative | 105/298 (35%) | 106/335 (32%) | 154/335 (46%) | 51/335 (15%) | 133/335 (40%) | 105/335 (31%) | 154/335 (46%) |
| Squamous cell carcinoma | 23/86 (27%) | 42/91 (46%) | 48/91 (53%) | 18/91 (20%) | 30/91 (33%) | 57/91 (63%) | 69/91 (76%) |
PCR - polymerase chain reaction, TC - tumor cells, IC - immune cells, EGFR - epidermal growth factor receptor mutations, ALK - anaplastic lymphoma kinase rearrangements.